LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP2509 is a selective and reversible LSD1 inhibitor with an IC50 of 10nM. SP2509 demonstrates a high specificity for LSD1, with no effect on MAOi. Synonyms: (E)-N-(1-(5-chloro-2- hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, SP-2509 CAS No: 1423715-09-6 Molecular Weight: 437.9 Molecular Formula: C19H20ClN3O5S Appearance: Supplied as a solid. Purity: 95% (HPLC) Solubility: DMSO Storage and Stability: Store and 4C for short term, -20C for long term storage. Stable for at least 2 years after receipt when stored at -20C.
Molecular Weight:
437.9
Purity:
95% (HPLC)
Form:
Supplied as a solid.
CAS Number:
[1423715-09-6]
* VAT and and shipping costs not included. Errors and price changes excepted
